ZyVersa Therapeutics
Weston
About ZyVersa Therapeutics
ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. Our focus is on patients with inflammatory or renal diseases who have significant unmet medical needs. Our development pipeline includes a novel inflammasome inhibitor with potential to treat multiple inflammatory diseases, and phase 2a-ready VAR 200, a cholesterol efflux mediator for treatment of a rare kidney disease, focal segmental glomerulosclerosis (FSGS), with potential to treat other kidney diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $25.7M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2025)
- Ticker: nasdaq:ZVSA
- Website: zyversa.com
Industries & Categories
Health Care, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/zyversa-therapeutics-85362 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.